Acadia Pharmaceuticals Inc (NASDAQ:ACAD) currently has a daily average trading volume of 1.42M but it saw 1363078 shares traded in last market. With a market cap of 2.87B USD, the company’s current market price of $17.26 came falling about -4.22 while comparing to the previous closing price of $18.02. In past 52 weeks, the stock remained buoying in the range of price level as high as $32.59 and as low as $14.15. In the recent trading on the day, stock has struck highest price mark of $17.25 while lowest mark touched by it was $18.19.
Taking a look at 20-day trading activity of Acadia Pharmaceuticals Inc (ACAD) gives us an average price of $16.89, while its current price level is -47.04% below from 52-week high level whereas it is 21.98% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $15.93 while that of 200 days or SMA-200 reads an average of $16.71. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.69% during that period while stretching the period over a month that decreases to 4.20%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.74 which implies that the stock is in neutral territory.
Morgan Stanley downgraded its recommendation for the stock as a “Equal-Weight” from “Overweight” on August 07, 2024 while assigning a price target range of $28-$20. BMO Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $31.
Over the week, ACAD’s stock price is moving 3.29% up while it is -3.74% when we observe its performance for the past one month. Year-to-date it is -44.87% down and over the past year, the stock is showing a downside performance of -18.47%.
Currently, Acadia Pharmaceuticals Inc’s total number of outstanding shares is 166.35M. Company’s return on investment (ROI) stands at 20.81% and return on equity (ROE) at 27.36%. It has a price to earnings ratio (P/E ratio) of 22.34 while having a 22.63 of forward P/E ratio. Stock’s beta reads 0.40. Stock has a price to book (P/B) ratio of 4.97 while price to sale or P/S ratio amounts to 3.09. Its return on asset (ROA) is 15.97% on average.
